NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as ESPERION THERAPS INC. It is marketed under 1 brand name, including NEXLIZET. Available in 1 different strength, such as 180MG;10MG, and administered through 1 route including TABLET;ORAL.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"96898","ingredient":"BEMPEDOIC ACID; EZETIMIBE","trade_name":"NEXLIZET","family_id":"d960642d47724202905c","publication_number":"US7335799B2","cleaned_patent_number":"7335799","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-12-03","publication_date":"2008-02-26","legal_status":"Granted"} | US7335799B2 Molecular | 26 Feb, 2008 | Granted | 03 Dec, 2030 | |
| {"application_id":"96920","ingredient":"BEMPEDOIC ACID; EZETIMIBE","trade_name":"NEXLIZET","family_id":"712bfa46d78c49b1ad86","publication_number":"US10912751B2","cleaned_patent_number":"10912751","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-03-14","publication_date":"2021-02-09","legal_status":"Granted"} | US10912751B2 | 09 Feb, 2021 | Granted | 14 Mar, 2036 | |
| {"application_id":"96941","ingredient":"BEMPEDOIC ACID; EZETIMIBE","trade_name":"NEXLIZET","family_id":"712bfa46d78c49b1ad86","publication_number":"US11744816B2","cleaned_patent_number":"11744816","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-03-14","publication_date":"2023-09-05","legal_status":"Granted"} | US11744816B2 | 05 Sep, 2023 | Granted | 14 Mar, 2036 | |
| {"application_id":"112791","ingredient":"BEMPEDOIC ACID; EZETIMIBE","trade_name":"NEXLIZET","family_id":"e385a82c57b34e86804e","publication_number":"US11613511B2","cleaned_patent_number":"11613511","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-06-19","publication_date":"2023-03-28","legal_status":"Granted"} | US11613511B2 Molecular | 28 Mar, 2023 | Granted | 19 Jun, 2040 | |
| {"application_id":"112811","ingredient":"BEMPEDOIC ACID; EZETIMIBE","trade_name":"NEXLIZET","family_id":"e385a82c57b34e86804e","publication_number":"US11760714B2","cleaned_patent_number":"11760714","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-06-19","publication_date":"2023-09-19","legal_status":"Granted"} | US11760714B2 Formulation | 19 Sep, 2023 | Granted | 19 Jun, 2040 | |
| {"application_id":"116651","ingredient":"BEMPEDOIC ACID; EZETIMIBE","trade_name":"NEXLIZET","family_id":"e385a82c57b34e86804e","publication_number":"US11926584B2","cleaned_patent_number":"11926584","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-06-19","publication_date":"2024-03-12","legal_status":"Granted"} | US11926584B2 | 12 Mar, 2024 | Granted | 19 Jun, 2040 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Bempedoic Acid; Ezetimibe
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.